In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 406-412

  Chen, Yanzuo ^a   Yang, Wuli ^a   Chang, Baisong ^a   Hu, Hangting ^a   Fang, Xiaoling ^a   Sha, Xianyi ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antitumor activity; Doxorubicin; Mesoporous silica nanoparticles; N isopropylacrylamide co methacrylic acid; Nanoparticles; Safety evaluation

Indexed keywords

DOXORUBICIN; MESOPOROUS SILICA NANOPARTICLE; METHACRYLIC ACID DERIVATIVE; NANOCARRIER; NANOPARTICLE; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL SUSPENSION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOXICITY; HEART MUSCLE INJURY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEAN RESIDENCE TIME; MOUSE; MUSCLE ATROPHY; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; RAT; SARCOMA 180; TISSUE DISTRIBUTION; TUMOR VOLUME; WEIGHT REDUCTION;

3-(4,5-DIMETHYL-THIAZOL-2-YL)-2,5-DIPHENYL-TETRAZOLIUM BROMIDE; ANTITUMOR ACTIVITY; APPARENT VOLUME OF DISTRIBUTION; AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE; ASPARTATE TRANSAMINASE; AST; AUC; CK; CL; CLEARANCE; CREATINE KINASE; DL%; DOX; DOX-LOADED MSN; DOX-LOADED P-MSN; DOXIL; DOXORUBICIN; DRUG-LOADING COEFFICIENT; ELIMINATION HALF-LIFE; ENCAPSULATION RATIO; ENHANCED PERMEABILITY AND RETENTION; EPR; ER%; MEAN RESIDENCE TIME; MESOPOROUS SILICA NANOPARTICLES; MRT; MSN; MSN-DOX; MTT; N-ISOPROPYLACRYLAMIDE-CO-METHACRYLIC ACID; NANOPARTICLES; P (NIPAM-CO-MAA); P (NIPAM-CO-MAA) COATED MSN; P-MSN; P-MSN-DOX; PEG-LIPOSOME OF DOX; POLY (N-ISOPROPYLACRYLAMIDE-CO-METHACRYLIC ACID); RBC; RED BLOOD CELL; RES; RETICULO-ENDOTHELIAL SYSTEM; SAFETY EVALUATION; T(1/2)(Β); V(D); VOLUME PHASE TRANSITION TEMPERATURE; VPTT; WBC; WHITE BLOOD CELL;

ACRYLAMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; POLYMETHACRYLIC ACIDS; POROSITY; RATS; RATS, SPRAGUE-DAWLEY; SARCOMA 180; SILICON DIOXIDE; TISSUE DISTRIBUTION; TOXICITY TESTS, SUBACUTE;

EID: 84888326980     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.06.015     Document Type: Article

References (38)

1. X.B. Xiong, Z. Ma, R. Lai, and A. Lavasanifar The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin Biomaterials 31 2010 757 768
2. K. Kiyomiya, S. Matsuo, and M. Kurebe Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex Cancer Res. 61 2001 2467 2471
3. E. Gianasi, M. Wasil, E.G. Evagorou, A. Keddle, G. Wilson, and R. Duncan HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo Eur. J. Cancer 35 1999 994 1002
4. V. Omelyaneko, P. Kopecková, C. Gentry, and J. Kopecek Targetable HPMA copolymer adriamycin conjugates. Recognition, internalization, and subcellular fate J. Control. Release 53 1998 25 37
5. N. Lavignac, J.L. Nicholls, P. Ferruti, and R. Duncan Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker Macromol. Biosci. 9 2009 480 487
6. H. Guan, M.J. McGuire, S. Li, and K.C. Brown Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers Bioconjug. Chem. 19 2008 1813 1821
7. T. Etrych, P. Chytil, T. Mrkvan, M. Sírová, B. Ríhová, and K. Ulbrich Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting J. Control. Release 132 2008 184 192
8. J. Lu, M. Liong, Z. Li, J.I. Zink, and F. Tamanoi Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals Small 6 2010 1794 1805
9. I.I. Slowing, J.L. Vivero-Escoto, C.W. Wu, and V.S. Lin Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers Adv. Drug. Deliv. Rev. 60 2008 1278 1288
10. J.L. Vivero-Escoto, I.I. Slowing, B.G. Trewyn, and V.S. Lin Mesoporous silica nanoparticles for intracellular controlled drug delivery Small 6 2010 1952 1967
11. M. Vallet-Regi, F. Balas, and D. Arcos Mesoporous materials for drug delivery Angew. Chem. Int. Ed. Engl. 46 2007 7548 7558
12. B. Chang, X. Sha, J. Guo, Y. Jiao, C. Wang, and W. Yang Thermo and pH dual responsive, polymer shell coated, magnetic mesoporous silica nanoparticles for controlled drug release J. Mater. Chem. 21 2011 9239 9247
13. C.F.L. Ken, T.D. Nguyen, J.F. Stoddart, and J.I. Zink Supramolecular nanovalves controlled by proton abstraction and competitive binding Chem. Mater. 18 2006 5919 5928
14. D. Schmaljohann Thermo- and pH-responsive polymers in drug delivery Adv. Drug Deliv. Rev. 58 2006 1655 1670
15. E. Roux, C. Passirani, S. Scheffold, J.P. Benoit, and J.C. Leroux Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes J. Control. Release 94 2004 447 451
16. T. Yu, D. Hubbard, A. Ray, and H. Ghandehari In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics J. Control. Release 163 2012 46 54
17. H. Meng, M. Xue, T. Xia, Z. Ji, D.Y. Tarn, J.I. Zink, and A.E. Nel Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model ACS Nano 5 2011 4131 4144
18. Y. Sheng, C. Liu, Y. Yuan, X. Tao, F. Yang, X. Shan, H. Zhou, and F. Xu Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan Biomaterials 30 2009 2340 2348
19. J. Lu, M. Liong, J.I. Zink, and F. Tamanoi Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs Small 3 2007 1341 1346
20. L. Dong, S. Xia, K. Wu, Z. Huang, H. Chen, J. Chen, and J. Zhang A pH/enzyme-responsive tumor-specific delivery system for doxorubicin Biomaterials 31 2010 6309 6316
21. S.D. Li, and L. Huang Pharmacokinetics and biodistribution of nanoparticles Mol. Pharm. 5 2008 496 504
22. D.R. Owens, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
23. H. Kobayashi, S. Kawamoto, T. Saga, N. Sato, A. Hiraga, T. Ishimori, J. Konishi, K. Togashi, and M.W. Brechbiel Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents Magn. Reson. Med. 46 2001 781 788
24. J.S. Souris, C.H. Lee, S.H. Cheng, C.T. Chen, C.S. Yang, J.A. Ho, C.Y. Mou, and L.W. Lo Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles Biomaterials 31 2010 5564 5574
25. C.H. Lee, S.H. Cheng, Y.J. Wang, Y.C. Chen, N.T. Chen, J. Souris, C.T. Chen, C.Y. Mou, C.S. Yang, and L.W. Lo Near-infrared mesoporous silica nanoparticles for optical imaging: characterization and in vivo biodistribution Adv. Funct. Mater. 19 2009 215 222
26. S. Zhu, M. Hong, G. Tang, L. Qian, J. Lin, Y. Jiang, and Y. Pei Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style Biomaterials 31 2010 1360 1371
27. W. Zhang, Y. Shi, Y. Chen, J. Hao, X. Sha, and X. Fang The potential of pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models Biomaterials 32 2011 5934 5944
28. P. Deol, and G.K. Khuller Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice Biochim. Biophys. Acta 1334 1997 161 172
29. Y. Jiang, X. Jiang, K. Law, Y. Chen, J. Gu, W. Zhang, H. Xin, X. Sha, and X. Fang Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-beta-cyclodextrin and safety evaluation Int. J. Pharm. 415 2011 252 258
30. W. Zhang, Y. Shi, Y. Chen, S. Yu, J. Hao, J. Luo, X. Sha, and X. Fang Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance Eur. J. Pharm. Biopharm. 75 2010 341 353
31. S.M. DeAtley, M.Y. Aksenov, M.V. Aksenova, B. Jordan, J.M. Carney, and D.A. Butterfield Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture Toxicology 134 1999 51 62
32. Y. Xin, G. Zhou, Z. Deng, Y. Chen, Y. Wu, P. Xu, and Y. Xuan Protective effect of lycium barbarum on doxorubicin-induced cardiotoxicity Phytother. Res. 21 2007 1020 1024
33. A.L. Ferreira, L.S. Matsubara, and B.B. Matsubara Anthracycline-induced cardiotoxicity Cardiovasc. Hematol. Agents Med. Chem. 6 2008 278 281
34. A.B. Combs, and D. Acosta Toxic mechanisms of the heart: a review Toxicol. Pathol. 18 1990 583 596
35. V.J. Ferrans Overview of cardiac pathology in relation to anthracycline cardiotoxicity Cancer Treat. Rep. 62 1978 955 961
36. B. Weisblum, and E. Haenssler Fluorometric properties of the bibenzimidazole derivative Hoechst 33258, a fluorescent probe specific for AT concentration in chromosomal DNA Chromosoma 46 1974 255 260
37. H.D. Han, A. Lee, C.K. Song, T. Hwang, H. Seong, C.O. Lee, and B.C. Shin In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes Int. J. Pharm. 313 2006 181 188
38. W.L. Lu, X.R. Qi, Q. Zhang, R.Y. Li, G.L. Wang, R.J. Zhang, and S.L. Wei A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug J. Pharmacol. Sci. 95 2004 381 389